为了研究复方苦参注射液（CKI）在预防和治疗宫颈癌中的分子靶点和机制，基于网络药理学和转录组学方法。本研究采用网络药理学方法筛选有效化合物，将网络药理学和RNA-seq的结果进行整合，综合筛选和预测靶基因，分析靶基因的生物学功能和信号通路，并构建蛋白质相互作用网络以筛选关键基因。结果通过生物实验，分子对接，RT-PCR和西方印迹分析进一步验证。结果显示，CXCL2、抗血管内皮生长因子和己糖激酶2等关键基因是CKI治疗宫颈癌的治疗靶点。这些靶点在癌症通路、细胞周期、MAPK信号通路等主要通路中显著富集。体外细胞实验显示，CKI能有效抑制癌细胞的增殖，促进凋亡，诱导细胞周期阻滞。RT-PCR和西方印迹实验证明，关键基因的表达显著降低。化合物对关键基因具有良好的结合活性。CKI通过其活性成分，通过多靶点和多通路，能够在细胞周期的某个阶段阻断宫颈癌细胞的生长并引起凋亡，证明了CKI在治疗宫颈癌方面的效果。 版权所有©2023年作者。由Wolters Kluwer Health, Inc.出版。

To investigate the molecular targets and mechanisms of compound kushen injection (CKI) in the prevention and treatment of cervical cancer based on network pharmacology and transcriptomics.In this study, we used network pharmacology methods to screen for effective compounds, integrated the results of network pharmacology and RNA-seq to comprehensively screen and predict target genes, analyze the biological functions and signaling pathways of target genes, and construct a PPI network to screen for hub genes. The results were further verified by biological experiments, molecular docking, RT-PCR, and western blot analysis.The results showed that the hub genes CXCL2, anti-vascular endothelial growth factor, hexokinase 2 are therapeutic targets of CKI for the treatment of Cervical Cancer. These targets were significantly enriched in pathways mainly including pathways in cancer, cell cycle, MAPK signaling pathways, etc. In vitro cell experiments showed that CKI could effectively inhibit the proliferation of cancer cells, promote apoptosis, and induce cell cycle arrest. RT-PCR and western blot experiments showed that the expression of hub genes was significantly decreased. The compounds have good binding activity to hub genes.CKI, based on its active ingredients and through multiple targets and multiple pathways, can stop the growth of cervical cancer cells at a certain phase of the cell cycle and cause apoptosis, which proved CKI's effect in treating cervical cancer.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.